Blau Farmaceutica SA
BOVESPA:BLAU3

Watchlist Manager
Blau Farmaceutica SA Logo
Blau Farmaceutica SA
BOVESPA:BLAU3
Watchlist
Price: 14.7 BRL -2.13% Market Closed
Market Cap: 2.6B BRL
Have any thoughts about
Blau Farmaceutica SA?
Write Note

Blau Farmaceutica SA
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Blau Farmaceutica SA
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Blau Farmaceutica SA
BOVESPA:BLAU3
Interest Income Expense
R$14.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biomm SA
BOVESPA:BIOM3
Interest Income Expense
-R$76k
CAGR 3-Years
80%
CAGR 5-Years
60%
CAGR 10-Years
N/A
No Stocks Found

Blau Farmaceutica SA
Glance View

Market Cap
2.6B BRL
Industry
Biotechnology

Blau Farmacêutica SA engages in the manufacturing of pharmaceuticals. The company is headquartered in Cotia, Sao Paulo and currently employs 1,700 full-time employees. The company went IPO on 2021-04-19. The firm focuses on the development, production and commercialization of medicines, which aim at treatment in the areas of oncology, nephrology, hematology and infectology, among others. Its product lines includes biopharmaceuticals, biosimilars, oncological - injectable, oncological - oral, blood products, antiviral and antiretrovirals, uterine stimulators, anaesthetics, antithrombotics, thrombolytics, female health care, antibiotics, non-beta lactams, cephalosporin, chloramphenicol, acid pumper inhibitor and other hospital products. The firm operates in Brazil, Argentina, Colombia, Peru, Uruguay, Chile and the United States, having a pharmaceutical industrial complex composed of five industrial plants, dedicated to the production of biological, biotechnological and oncological medicines, antibiotics, injectable anesthetics and biotechnological inputs.

BLAU3 Intrinsic Value
23.42 BRL
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Blau Farmaceutica SA's Interest Income Expense?
Interest Income Expense
14.9m BRL

Based on the financial report for Dec 31, 2023, Blau Farmaceutica SA's Interest Income Expense amounts to 14.9m BRL.

What is Blau Farmaceutica SA's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
-32%

Over the last year, the Interest Income Expense growth was -32%.

Back to Top